Galiè N. Humbert M. Vachiery J.L. et al.

[2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension].

Kardiol Pol. 73: 1127-1206Hoeper M.M. Bogaard H.J. Condliffe R. et al.

Definitions and diagnosis of pulmonary hypertension.

J Am Coll Cardiol. 62: D42-D50Simonneau G. Montani D. Celermajer D.S. et al.

Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Eur Respir J. 53https://doi.org/10.1183/13993003.01913-2018Galiè N. Corris P.A. Frost A. et al.

Updated treatment algorithm of pulmonary arterial hypertension.

J Am Coll Cardiol. 62: D60-D72Marra A.M. Benjamin N. Eichstaedt C. et al.

Gender-related differences in pulmonary arterial hypertension targeted drugs administration.

Pharmacol Res. 114: 103-109Batton K.A. Austin C.O. Bruno K.A. et al.

Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease.

Biol Sex Differ. 9: 15

Molecular pathogenesis of pulmonary arterial hypertension.

J Clin Invest Dec. 122: 4306-4313Lahm T. Tuder R.M. Petrache I.

Progress in solving the sex hormone paradox in pulmonary hypertension.

Am J Physiol Lung Cell Mol Physiol. 307: L7-L26

Right Heart Failure in Pulmonary Hypertension.

Cardiol Clin May. 38: 243-255Bogaard H.J. Abe K. Vonk Noordegraaf A. et al.

The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension.

Chest Mar. 135: 794-804Tonelli A.R. Arelli V. Minai O.A. et al.

Causes and circumstances of death in pulmonary arterial hypertension.

Am J Respir Crit Care Med. 188: 365-369Hester J. Ventetuolo C. Lahm T.

Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Compr Physiol. 10: 125-170Franco V. Ryan J.J. McLaughlin V.V.

Pulmonary Hypertension in Women.

Heart Fail Clin Jan. 15: 137-145Baethge C. Goldbeck-Wood S. Mertens S.

SANRA-a scale for the quality assessment of narrative review articles.

Res Integr Peer Rev. 4: 5O'Neill Z.R. Raparelli V. Norris C.M. et al.

Demystifying how to incorporate Sex and Gender into cardiovascular research: a practical guide.

Can J Cardiol. https://doi.org/10.1016/j.cjca.2022.05.017

REVEAL: a contemporary US pulmonary arterial hypertension registry.

Eur Respir Rev Mar 01. 21: 8-18Escribano-Subias P. Blanco I. López-Meseguer M. et al.

Survival in pulmonary hypertension in Spain: insights from the Spanish registry.

Eur Respir J Sep. 40: 596-603

Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension.

Eur J Med Res Sep 28. 14: 433-442Austin E.D. Cogan J.D. West J.D. et al.

Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.

Eur Respir J Nov. 34: 1093-1099Ventetuolo C.E. Ouyang P. Bluemke D.A. et al.

Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study.

Am J Respir Crit Care Med Mar 01. 183: 659-667Ventetuolo C.E. Praestgaard A. Palevsky H.I. et al.

Sex and haemodynamics in pulmonary arterial hypertension.

Eur Respir J Feb. 43: 523-530

Pulmonary Arterial Hypertension in Women.

Methodist Debakey Cardiovasc J. 13: 224-237Jones R.D. English K.M. Pugh P.J. et al.

Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action.

J Cardiovasc Pharmacol Jun. 39: 814-823Lahm T. Crisostomo P.R. Markel T.A. et al.

Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism.

Am J Physiol Regul Integr Comp Physiol Nov. 295: R1486-R1493Lahm T. Patel K.M. Crisostomo P.R. et al.

Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle.

Am J Physiol Endocrinol Metab Sep. 293: E865-E871Sun Y. Sangam S. Guo Q. et al.

Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension.

Front Cardiovasc Med. 8: 719058Ventetuolo C.E. Baird G.L. Barr R.G. et al.

Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.

Am J Respir Crit Care Med. 193: 1168-1175Baird G.L. Archer-Chicko C. Barr R.G. et al.

Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension.

Eur Respir J. 51https://doi.org/10.1183/13993003.00467-2018Mair K.M. Wright A.F. Duggan N. et al.

Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Am J Respir Crit Care Med. 190: 456-467White K. Johansen A.K. Nilsen M. et al.

Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

Circulation. 126: 1087-1098Deng Z. Morse J.H. Slager S.L. et al.

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Am J Hum Genet Sep. 67: 737-744Soubrier F. Chung W.K. Machado R. et al.

Genetics and genomics of pulmonary arterial hypertension.

J Am Coll Cardiol. 62: D13-D21Morrell N.W. Aldred M.A. Chung W.K. et al.

Genetics and genomics of pulmonary arterial hypertension.

Eur Respir J. 53https://doi.org/10.1183/13993003.01899-2018Best D.H. Sumner K.L. Smith B.P. et al.

EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension.

Chest. 04. 151: 821-828Evans J.D. Girerd B. Montani D. et al.

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.

Lancet Respir Med Feb. 4: 129-137Akinyemi R. Arnett D.K. Tiwari H.K. et al.

Interleukin-6 (IL-6) rs1800796 and cyclin dependent kinase inhibitor (CDKN2A/CDKN2B) rs2383207 are associated with ischemic stroke in indigenous West African Men.

J Neurol Sci. 379: 229-235Varghese M. Griffin C. McKernan K. et al.

Sex Differences in Inflammatory Responses to Adipose Tissue Lipolysis in Diet-Induced Obesity.

Endocrinology. 160: 293-312

Tubular carcinoma of the male breast: report of a case.

Cancer Aug. 36: 462-465Stein M.M. Conery M. Magnaye K.M. et al.

Sex-specific differences in peripheral blood leukocyte transcriptional response to LPS are enriched for HLA region and X chromosome genes.

Sci Rep. 11: 1107Gemmati D. Bramanti B. Serino M.L. et al.

COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?.

Int J Mol Sci. 21https://doi.org/10.3390/ijms21103474Jacobs W. van de Veerdonk M.C. Trip P. et al.

The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension.

Chest Jun. 145: 1230-1236D'Alonzo G.E. Barst R.J. Ayres S.M. et al.

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Ann Intern Med. 115: 343-349Ryan J.J. Huston J. Kutty S. et al.

Right ventricular adaptation and failure in pulmonary arterial hypertension.

Can J Cardiol Apr. 31: 391-406

Imaging the heart in pulmonary hypertension: an update.

Eur Respir Rev Dec. 24: 653-664

Sex matters in pulmonary arterial hypertension.

Eur Respir J Aug. 44: 553-554Galié N. Manes A. Branzi A.

The endothelin system in pulmonary arterial hypertension.

Cardiovasc Res Feb. 61: 227-237Schermuly R.T. Ghofrani H.A. Wilkins M.R. et al.

Mechanisms of disease: pulmonary arterial hypertension.

Nat Rev Cardiol. 8: 443-455Miyauchi T. Yanagisawa M. Iida K. et al.

Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects.

Am Heart J Apr. 123: 1092-1093Polderman K.H. Stehouwer C.D. van Kamp G.J. et al.

Influence of sex hormones on plasma endothelin levels.

Ann Intern Med Mar 15. 118: 429-432Stauffer B.L. Westby C.M. Greiner J.J. et al.

Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults.

Am J Physiol Regul Integr Comp Physiol Feb. 298: R261-R265Galiè N. Humbert M. Vachiery J.L. et al.

2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

Rev Esp Cardiol. 69: 177Dingemanse J. van Giersbergen P.L.

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

Clin Pharmacokinet. 43: 1089-1115Galiè N. Ghofrani H.A. Torbicki A. et al.

Sildenafil citrate therapy for pulmonary arterial hypertension.

N Engl J Med. 353: 2148-2157Chan M.V. Bubb K.J. Noyce A. et al.

Distinct endothelial pathways underlie sexual dimorphism in vascular auto-regulation.

Br J Pharmacol. 167: 805-817Mathai S.C. Hassoun P.M. Puhan M.A. et al.

Sex differences in response to tadalafil in pulmonary arterial hypertension.

Chest. 147: 188-197Galiè N. Palazzini M. Manes A.

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses.

Eur Heart J. 31: 2080-2086Forte P. Kneale B.J. Milne E. et al.

Evidence for a difference in nitric oxide biosynthesis between healthy women and men.

Hypertension. 32: 730-734Marra A.M. Egenlauf B. Ehlken N. et al.

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Int J Cardiol. 195: 19-26Galiè N. Channick R.N. Frantz R.P. et al.

Risk stratification and medical therapy of pulmonary arterial hypertension.

Eur Respir J. 53https://doi.org/10.1183/13993003.01889-2018Frey R. Saleh S. Becker C. et al.

Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Pulm Circ. 6: S58-S65Barst R.J. Rubin L.J. Long W.A. et al.

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

N Engl J Med. 334: 296-301Rubin L.J. Mendoza J. Hood M. et al.

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

Ann Intern Med. 112: 485-491

Pathways in pulmonary arterial hypertension: the future is here.

Eur Respir Rev. 21: 321-327Humbert M. McLaughlin V. Gibbs J.S.R. et al.

Sotatercept for the Treatment of Pulmonary Arterial Hypertension.

N Engl J Med. 384: 1204-1215Mauvais-Jarvis F. Bairey Merz N. Barnes P.J. et al.

Sex and gender: modifiers of health, disease, and medicine.

Lancet. 396: 565-582Johnson J.L. Greaves L. Repta R.

Better science with sex and gender: Facilitating the use of a sex and gender-based analysis in health research.

Int J Equity Health. 8: 14Turner G.A. Amoura N.J. Strah H.M.

Care of the Transgender Patient with a Pulmonary Complaint.

Ann Am Thorac Soc. 18: 931-937Mai A.S. Lim O.Z.H. Ho Y.J. et al.

Prevalence, Risk Factors and Intervention for Depression and Anxiety in Pulmonary Hypertension: A Systematic Review and Meta-analysis.

Front Med (Lausanne). 9: 765461Löwe B. Gräfe K. Ufer C. et al.

Anxiety and depression in patients with pulmonary hypertension.

Psychosom Med. 66: 831-836Harzheim D. Klose H. Pinado F.P. et al.

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Respir Res. 14: 104Armstrong I. Rochnia N. Harries C. et al.

The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study.

BMJ Open. 2: e000806Kingman M. Hinzmann B. Sweet O. et al.

Living with pulmonary hypertension: unique insights from an international ethnographic study.

BMJ Open. 4: e004735Von Visger T.T. Kuntz K.K. Phillips G.S. et al.

Quality of life and psychological symptoms in patients with pulmonary hypertension.

Heart Lung. 47: 115-121Guillevin L. Armstrong I. Aldrighetti R. et al.

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives.

Eur Respir Rev. 22: 535-542Fuge J. Park D.H. von Lengerke T. et al.

Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study.

Front Psychiatry. 12: 781532Taichman D.B. Shin J. Hud L. et al.

Health-related quality of life in patients with pulmonary arterial hypertension.

Respir Res. 6: 92McGoon M.D. Ferrari P. Armstrong I. et al.

The importance of patient perspectives in pulmonary hypertension.

Eur Respir J. 53https://doi.org/10.1183/13993003.01919-2018Matura L.A. McDonough A. Carroll D.L.

Health-related quality of life and psychological states in patients with pulmonary arterial hypertension.

J Cardiovasc Nurs. 29: 178-184Manes A. Palazzini M. Dardi F. et al.

[Female gender and pulmonary arterial hypertension: a complex relationship].

G Ital Cardiol (Rome). 13: 448-460Dai L.L. Jiang T.C. Li P.F. et al.

Predictors of Maternal Death Among Women With Pulmonary Hypertension in China From 2012 to 2020: A Retrospective Single-Center Study.

Front Cardiovasc Med. 9: 814557Montani D. Lau E.M. Descatha A. et al.

Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.

Eur Respir J. 46: 1721-1731

Pertussis vaccine: court finds no justification for association with permanent brain damage.

Lancet. 1: 837Chao H.Y. Hsu C.H. Wang S.T. et al.

Mediating effect of social support on the relationship between illness concealment and depression symptoms in patients with pulmonary arterial hypertension.

Heart Lung. 50: 706-713Talwar A. Garcia J.G.N. Tsai H. et al.

Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement.

Am J Respir Crit Care Med. 196: e32-e47Talwar A. Sahni S. Kohn N. et al.

Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation.

Pulm Circ. 6: 191-195Wu W.H. Yang L. Peng F.H. et al.

Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension.

Am J Respir Crit Care Med. 187: 303-310McGettrick M. McCaughey P. MacLellan A. et al.

Social deprivation in Scottish populations with pulmonary hypertension secondary to connective tissue disease and chronic thromboembolic disease.

ERJ Open Res Oct. 6https://doi.org/10.1183/23120541.00297-2019

Socioeconomic status and survival in patients with pulmonary hypertension.

ERJ Open Res. 6https://doi.org/10.1183/23120541.00638-2020Alquraishi 1 JS H. Lee 2 L. Legkaia 2 L. et al.Division of Medicine UoBC, Vancouver, BCCanada DoR, University of British ColumbiaVancouver, BC, Canada3 Centre for Health Evaluation and Outcome SciencesUniversity of British ColumbiaVancouver, BC, Canada MUniversity of AlbertaEdmonton, AB, CanadaRespiratory Division,Vancouver General Hospital V, BC, CanadaCardiology, University of British ColumbiaVancouver, BC, Canada

The Association Between Median Income and Severity of Pulmonary Hypertension at Diagnosis and Risk at Follow Up in a Public Health Care System.

Am J Respir Crit Care Med. ()https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5085Azkan Ture D. Bhattacharya S. Demirci H. et al.

Health Literacy and Health Outcomes in Chronic Obstructive Pulmonary Disease Patients: An Explorative Study.

Front Public Health. 10: 846768Cascino T.M. Ashur C. Richardson C.R. et al.

Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States.

Pulm Circ. 10 ()Sliwa K. Davison B.A. Mayosi B.M. et al.

Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry.

Eur Heart J. 34: 3151-3159Moran-Mendoza O. Pérez-Padilla J.R. Salazar-Flores M. et al.

Wood smoke-associated lung disease: a clinical, functional, radiological and pathological description.

Int J Tuberc Lung Dis. 12: 1092-1098Sandoval J. Salas J. Martinez-Guerra M.L. et al.

Pulmonary arterial hypertension and cor pulmonale associated with chronic domestic woodsmoke inhalation.

Chest. 103: 12-20Thenappan T. Shah S.J. Rich S. et al.

Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

Eur Respir J. 35: 1079-1087Peacock A.J. Murphy N.F. McMurray J.J. et al.

An epidemiological study of pulmonary arterial hypertension.

Eur Respir J. 30: 104-109Kawut S.M. Horn E.M. Berekashvili K.K. et al.

New predictors of outcome in idiopathic pulmonary arterial hypertension.

Am J Cardiol. 95: 199-203Humbert M. Sitbon O. Yaïci A. et al.

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

Eur Respir J. 36: 549-555Humbert M. Sitbon O. Chaouat A. et al.

Pulmonary arterial hypertension in France: results from a national registry.

Am J Respir Crit Care Med. 173: 1023-1030Humbert M. Sitbon O. Chaouat A. et al.

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Circulation. 122: 156-163Ling Y. Johnson M.K. Kiely D.G. et al.

Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Am J Respir Crit Care Med. 186: 790-796Olsson K.M. Delcroix M. Ghofrani H.A. et al.

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Circulation. 129: 57-65Pulido T. Adzerikho I. Channick R.N. et al.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

N Engl J Med. 369: 809-818Gaine S. Sitbon O. Channick R.N. et al.

Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.

Chest. 160: 277-286